The following five drugs, selected by an academic review panel, will be included in the initial trial:
Taking a new drug from the initial discovery stage through clinical testing and regulatory review is complicated, expensive, and often inefficient. Trials are difficult to initiate, subject to lengthy regulatory review, infrastructure-intensive, and reliant on the enrollment of volunteers—all obstacles compounded by the fact that trials for new drugs are almost always conducted separately, even when multiple drugs are being developed to treat the same condition. And while the rise of personalized medicine has improved many aspects of patient care, it has also exacerbated the challenges of running a clinical trial. Small, targeted patient populations have made it more difficult to recruit qualified patients. Reliance on genetic testing increases infrastructure costs and complexity.
FRIENDS OF CANCER RESEARCH
1800 M Street NW Suite 1050 | Washington, DC 20036